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Summary 28	
Myocardial infarction (MI) is a major cause of premature adult death. Compromised cardiac 29	
function after MI leads to chronic heart failure with systemic health complications and high 30	
mortality rate1. Effective therapeutic strategies are highly needed to improve the recovery of 31	
cardiac function after MI. More specifically, there is a major unmet need for a new class of 32	
drugs that improve cardiomyocyte contractility, because currently available inotropic 33	
therapies have been associated with high morbidity and mortality in patients with systolic 34	
heart failure2,3, or have shown a very modest risk reduction4. Microtubule detyrosination is 35	
emerging as an important mechanism of regulation of cardiomyocyte contractility5. Here, we 36	
show that deficiency of Microtubule-Affinity Regulating Kinase 4 (MARK4) substantially 37	
limits the reduction of left ventricular ejection fraction (LVEF) after acute MI in mice, 38	
without affecting infarct size or cardiac remodeling. Mechanistically, we provide evidence 39	
that MARK4 regulates cardiomyocyte contractility through promoting microtubule-associated 40	
protein 4 (MAP4) phosphorylation, thereby facilitating the access of Vasohibin 2 (VASH2), a 41	
tubulin carboxypeptidase (TCP), to microtubules for a-tubulin detyrosination. Our results 42	
show how cardiomyocyte microtubule detyrosination is finely tuned by MARK4 to regulate 43	
cardiac inotropy, and identify MARK4 as a promising druggable therapeutic target for 44	
improving cardiac function after MI.   45	
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Main 46	
Myocardial infarction, the main cause of ischaemic heart disease (IHD) and chronic heart 47	
failure, is a serious ischaemic syndrome in which the blood supply to the heart is blocked, 48	
thus causing substantial myocardial cell death and loss of function in the remaining viable 49	
cells6. Microtubule (MT) detyrosination, which is associated with DESMIN at force-50	
generating sarcomeres5, is upregulated in the failing hearts of patients with ischaemic 51	
cardiomyopathy5,7 and hypertrophic cardiomyopathies5,7,8, and suppression of microtubule 52	
detyrosination improves contractility in failing cardiomyocytes7. VASH1 or VASH2, coupled 53	
with a small vasohibin-binding protein (SVBP), forms TCP that are capable of tubulin 54	
detyrosination9,10. Depletion of VASH1 speeds contraction and relaxation in failing human 55	
cardiomyocytes11. Structural and biophysical studies have suggested that VASH interacts with 56	
the C-terminal tail of a-tubulin12-14. However, the regulatory mechanisms of this system are 57	
still poorly understood.  58	
 59	
Microtubule stability is regulated by microtubule-associated proteins (MAPs), including 60	
classical MAPs such as MAP2, MAP4, and Tau15. MAP4 is expressed in the cardiomyocytes 61	
and MAP4 level significantly increases in human hearts with cardiomyopathy7. MAP4 62	
dephosphorylation on microtubule network has been described in a feline model of pressure 63	
overload cardiac hypertrophy16, but the relationship of MAP4 phosphorylation with 64	
microtubule detyrosination has not been examined. MARK4 is an evolutionarily conserved 65	
serine-threonine kinase17,18 known to phosphorylate MAPs including Tau, MAP2 and MAP4, 66	
on KXGS motif within their microtubule-binding motif19-21. The phosphorylation of MAPs 67	
triggered by MARK induces conformational changes that alter MAPs association with 68	
microtubules, and thereby regulates microtubule dynamics19-21. MARK4 is expressed in the 69	
hearts20, however the role of MARK4 in the cardiomyocyte has not been studied. Here, we 70	
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examined whether MARK4 regulates the function of the failing cardiomyocyte through 71	
modulation of microtubule detyrosination.  72	
 73	
Heart function of Mark4-/- mice post-MI 74	
To evaluate the effect of MARK4 in the setting of IHD, we used a murine model of 75	
permanent left anterior descending (LAD) coronary artery ligation to induce a large 76	
MI22,23(Extended Data Fig.1a). We detected Mark4 mRNA (Fig.1a) and MARK4 protein 77	
(Fig.1b) expression in the heart tissues, peaking between day 3 and day 5 post-MI (Fig.1a-1c). 78	
MARK4 was almost exclusively detected in the cytoskeleton-enriched insoluble fraction of 79	
the whole heart extracts (Fig.1b), and was localized in the cardiomyocytes (Fig.1c; Extended 80	
Data Fig.2a). MARK4 deficient mice (Mark4-/-) displayed a remarkable preservation of 81	
LVEF, which was 63.6% (± 5.8 %) higher compared with their wild-type littermate controls 82	
on the first week post LAD surgery (Fig.1d), without any alteration of cardiac remodeling 83	
(Supplementary Table1). Interestingly, infarct scar size was similar between the two groups of 84	
mice (Fig.1e), indicating that the substantial difference in cardiac function between wild-type 85	
and Mark4-/- mice was not attributable to differences of size in viable cardiac tissues.  86	
 87	
MARK4 regulates cardiac contractility   88	
We found that the protective effect of MARK4 deficiency on the preservation of cardiac 89	
function was already apparent at 24 hours post-MI (Extended Data Fig.1b; Fig.2a), despite 90	
similar extent of myocardial injury, shown by comparable serum cardiac troponin I (cTnI) 91	
level (Fig.2b), and comparable infarct size analyzed by triphenyltetrazolium chloride (TTC) 92	
staining (Fig.2c), in Mark4-/- and wild-type mice. MARK4 has previously been shown to 93	
regulate NLRP3 activation in macrophages24,25, which could affect the outcome of post-94	
ischaemic injury given the role of NLRP3 inflammasome in this setting26,27. However, 95	
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MARK4 deficiency did not significantly alter local and systemic inflammatory responses to 96	
myocardial injury at day 3 post-MI (Supplementary Table 2; Extended Data Fig.2b) when the 97	
preservation of LVEF was already evident in Mark4-/- mice (Extended Data Fig.2c). 98	
Moreover, bone marrow transfer of Mark4-/- haematopoietic cells into wild-type mice 99	
(Extended Data Fig.1c; validation in Extended Data Fig.3a-3b) did not improve cardiac 100	
function after MI in comparison with the transfer of wild-type bone marrow cells (Fig.2d), 101	
indicating that the protective effect of MARK4 deficiency post-MI cannot be explained by the 102	
role of MARK4 in haematopoietic cells. In contrast, using an inducible conditional deletion of 103	
Mark4 in cardiomyocytes (Mark4cKO) (Extended Data Fig.1d; validation in Extended Data 104	
Fig.3c), we found a substantial preservation of LVEF in Mark4cKO mice post-MI, which was 105	
56.8% (± 6.2%) higher when compared with their littermate control mice at day one post-MI 106	
(Fig.2e). The protective effect seen in Mark4cKO started as early as the first day after MI and 107	
lasted until the end of the observation at four weeks post-MI (Fig.2e). Very impressively, 108	
Mark4cKO mice had only 4.3% (±3.8%) LVEF reduction at day one post-MI, as compared 109	
with 37.9% (±5.5 %) LVEF reduction in the control mice (Fig.2e), without any difference in 110	
infarct size (Extended Data Fig.3e). The data further show an impact of the remaining/viable 111	
MARK4-deficient cardiomyocytes on the contractile function. Collectively, our data 112	
demonstrate an intrinsic role of cardiomyocyte-expressed MARK4 in controlling cardiac 113	
function post-MI. 114	
 115	
To examine the effect of MARK4 on cardiomyocyte function, we subjected freshly isolated 116	
primary cardiomyocytes28 from wild-type and Mark4-/- mice to a single cell contractility assay 117	
using an electrical stimulator (Fig.2f-2j). We found that sarcomere peak shortening of isolated 118	
cardiomyocytes strongly correlated with the in vivo LVEF (Fig.2g), indicating that isolated 119	
cardiomyocyte contraction measured ex vivo reflects LVEF assessed in vivo (Fig.1d, Fig.2a, 120	
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and Fig.2e). At baseline (BL), wild-type and MARK4-deficient cardiomyocytes had similar 121	
levels of resting sarcomere length (Extended Data Fig.4a-4b), sarcomere peak shortening and 122	
contraction/relaxation velocities (Fig.2h-2j), an observation consistent with the absence of 123	
LVEF difference between wild-type and Mark4-/- mice prior to MI (Fig.1d). After MI, wild-124	
type cardiomyocytes displayed markedly reduced sarcomere shortening (lower by 22.5% 125	
±3.7%) (Fig.2h; Extended Data Fig.4c), with slower relaxation velocity (lower by 126	
25.2%±4.4%) (Fig.2j; Extended Data Fig.4e), when compared with cardiomyocytes isolated 127	
from wild-type mice without MI. Strikingly, although no difference in resting sarcomere 128	
length was observed between Mark4-/- and wild-type cardiomyocytes after MI (Extended Data 129	
Fig.4b), Mark4-/- cardiomyocytes displayed a greater level of sarcomere shortening (higher by 130	
36.0%±6.0%) (Fig.2h; Extended Data Fig.4d) together with a greater velocity during both the 131	
contraction (higher by 42.0%±6.9%) and relaxation (higher by 46.7%±7.5%) phases (Fig.2i-132	
2j; Extended Data Fig.4f) when compared with wild-type cells. Upstream changes of calcium 133	
influx in excitation-contraction coupling could contribute to the contractile alterations, 134	
however, we did not observe any significant difference of Ca2+ transients between the 135	
electrically stimulated Mark4-/- and wild-type cardiomyocytes at baseline or at day 3 post-MI 136	
(Extended Data Fig.4g-4m). These data strongly demonstrate that MARK4 deficiency 137	
substantially improves both contractile and relaxation functions of cardiomyocytes after MI.  138	
 139	
MARK4 alters microtubule detyrosination  140	
Detyrosinated MTs represent tunable, compression-resistant elements that impair cardiac 141	
function in the human failing hearts5,29. We confirmed that detyrosinated a-tubulin level was 142	
significantly higher in cardiomyocytes isolated from ischaemic hearts compared with 143	
cardiomyocytes isolated from sham animals, in contrast with the remaining cell pool (immune 144	
cells, fibroblast, endothelial cells) which did not display such a change in a-tubulin 145	
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detyrosination (Extended Data Fig.2d-2e). Previous data indicate that MARK4 affects 146	
posttranslational microtubule detyrosination and polyglutamylation in ciliated cells30. 147	
Therefore, we hypothesized that MARK4 deficiency may affect microtubule detyrosination in 148	
cardiomyocytes after MI. We found a significantly lower level of detyrosinated microtubules 149	
in whole heart tissue extracts (Fig.3a-3b), and in isolated cardiomyocytes (together with 150	
reduced polyglutamylated microtubules) (Fig.3e-3g; Extended Data Fig.2f-2g) of Mark4-/- 151	
mice compared with their littermate wild-type controls after MI. In the absence of MARK4, 152	
we observed reduced ratio of a-tubulin in the soluble fraction versus its level in the insoluble 153	
fraction (Fig.3c), indicating a reduced percentage of free tubulin level without MARK4. More 154	
interestingly, we found that the level of tubulin detyrosination inversely correlated with LVEF 155	
(Fig.3d), suggesting a major role of MARK4-dependent modulation of microtubule 156	
detyrosination in controlling cardiac function after MI.   157	
 158	
To further address the hypothesis that MARK4 deficiency improves cardiomyocyte 159	
contractility through its impact on microtubule detyrosination, we employed a genetic 160	
approach to overexpress tubulin tyrosine ligase (TTL) using an adenovirus system (Extended 161	
Data Fig.5a-5c) to reverse the effect of TCP31 (Fig.3h-3k). TTL overexpression robustly 162	
improved peak shortening (Fig.3i; Extended Data Fig.5d) and increased the velocity of both 163	
contraction and relaxation (Fig.3j-3k; Extended Data Fig.5g) of failing wild-type 164	
cardiomycytes7. However, overexpression of TTL could not further improve peak shortening 165	
(Fig. 3i; Extended Data Fig.5e) and contractile velocities of post-MI Mark4-/- cardiomyocytes 166	
(Fig. 3j-3k; Extended Data Fig.5h), consistent with the already low level of detyrosinated 167	
microtubules in Mark4-/- cardiomyocytes. We further confirmed these data by using a 168	
pharmacological approach with parthenolide (PTL) to inhibit microtubule 169	
detyrosination5,7(Extended Data Fig.5j-5s). Taken together, our data show that MARK4 170	
	 8	
regulates cardiac inotropic function through its impact on microtubule detyrosination in 171	
cardiomyocytes.  172	
 173	
MARK4 directs VASH2 access to MTs 174	
Detyrosination of a-tubulin preferentially occurs on polymerized microtubules32. Apart from 175	
binding to VASH, C-terminal tubulin tails of the polymerized microtubules are also important 176	
for MAP binding33,34. MAP4 bound to the C-terminal tubulin tail along the protofilament 177	
stabilizes the longitudinal contacts of the microtubule, and this interaction can affect other 178	
microtubule binding partners such as the motor protein Kinesin-134. MARK4, as a kinase, is 179	
expected to phosphorylate MAP4 on its KXGS motif (including S941 and S1073 in human 180	
MAP4, or S914 and S1046 in murine MAP4) within its microtubule-binding repeats19,20 181	
(Extended Data Fig.6a), and alters MAP4 binding status on the protofilament (Extended Data 182	
Fig.6b). We therefore hypothesized that MARK4, through modifying MAP4 phosphorylation, 183	
may affect VASH accessibility to C-terminal a-tubulin tail and therefore influence 184	
microtubule detyrosination. To address this, we firstly used an in vitro microtubule co-185	
sedimentation assay. Both MAP4 (Extended Data Fig.6c-6d) and VASH2/SVBP (Extended 186	
Data Fig.6e-6f) were able to incrementally bind to polymerized microtubules when 187	
incremental amounts were separately applied in the assays, consistent with the results of the 188	
past studies12,34. Interestingly, we found that VASH2/SVBP bound to polymerized 189	
microtubules gradually decreased in the presence of incremental amounts of previously bound 190	
MAP4 (with four microtubule-binding repeats, 4R-MAP4) (Fig.4a-4b). Therefore, these 191	
results support the hypothesis that the level of MAP4 occupancy on the polymerized 192	
microtubules influences the level of VASH2 access to the microtubule protofilaments.  193	
 194	
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To confirm this hypothesis in in vivo, we performed biochemical subcellular fractionation on 195	
primary cardiomyocytes isolated from non-ischaemic and ischaemic hearts of wild-type and 196	
Mark4-/- mice using a commercial kit, which we have validated (Extended Data Fig.7a-7b). 197	
We firstly confirmed that MAP4 was expressed in the cardiomyocytes and its level was 198	
higher post-MI (Extended Data Fig.7c), a result consistent with data showing that MAP4 199	
levels significantly increase in human hearts with cardiomyopathies7. MAP4 was detected in 200	
its S914 phosphorylated (within KXGS motif) form (pMAP4S914) in the pellet extraction 201	
buffer (PEB), and also in its S1046 form (pMAP4S1046) in the cytosolic extraction buffer 202	
(CEB) (Extended Data Fig.7c-7e). Knocking down MAP4 by small hairpin RNA (shRNA) in 203	
the isolated cardiomyocytes post-MI led to increased VASH2 levels in the PEB fraction, 204	
confirmed by both western blot and immunocytochemistry (Extended Data Fig.7f-7i), which 205	
was in line with the results of in vitro microtubule co-sedimentation assay (Fig.4a-4b). 206	
VASH2 was detected as a specific band (validated by specific knock-down using shRNA, 207	
Extended Data Fig.8a) of around 50 kDa in the PEB fraction (Extended Data Fig.8a-8b), 208	
higher than its theoretical molecular weight of 40 kDa, presumably due to the formation of a 209	
stable complex with SVBP, because adding a denaturing agent (urea) reduced its size to 210	
around 40 kDa (Extended Data Fig.8b). Upon MI, pMAP4S914 was detected as a 110 kDa 211	
form in the PEB fraction whereas pMAP4S1046 was detected as a 220 kDa form in the CEB 212	
fraction (Fig.4c and Extended Data Fig.7c). MAP4 was detected as giant puncta in the cytosol 213	
of cardiomyocytes isolated post-MI, and these puncta were barely present at baseline 214	
(Extended Data Fig.8c-8d). pMAP4S1046 (in the CEB fraction) formed oligomerized structures 215	
(at 440 kDa or higher) as revealed on the native gel (Extended Data Fig.8e-8f), and these 216	
pMAP4S1046 oligomers could be further reduced to the 220 kDa form in presence of urea as 217	
revealed on the denaturing gel (Extended Data Fig.8g). The data suggest that MAP4 218	
phosphorylation at S1046 is associated with its presence as oligomers/giant puncta in the 219	
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cytosol in situ. Our results are consistent with a structural model, in which S914 is within the 220	
weak microtubule binding repeat of MAP4, whereas S1046 is within the strong anchor point 221	
of MAP4 binding repeat to the microtubules34 (Extended Data Fig.6b), so that S1046 222	
phosphorylation can lead to detachment of MAP4 from polymerized microtubules and 223	
accumulation in the cytosol. Accordingly, a higher pMAP4S1046 level was strongly and 224	
positively correlated with increased VASH2 levels in the PEB fraction (there also was a 225	
weaker correlation between pMAP4S914 levels and VASH2 levels in the PEB fraction) 226	
(Extended Data Fig.7c, 7e) in wild-type cardiomyocytes, indicating an association between 227	
phosphorylated MAP4 (at S941 and S1046) levels and VASH2 levels on the polymerized 228	
microtubules. Strikingly, levels of pMAP4S914 and pMAP4S1046 were substantially reduced in 229	
Mark4-/- cardiomyocytes after MI (Fig.4c-4d), confirming S914 and S1046 of MAP4 as 230	
MARK4 kinase substrate sites. Reduced levels of pMAP4S1046 in the CEB fraction and 231	
pMAP4S914 in the PEB fraction correlated well with a reduced level of VASH2 in the PEB 232	
fraction (r2=0.6165, P=0.0025; r2=0.4529, P=0.0165, respectively) (Fig.4c-4e), with a 233	
stronger association between pMAP4S1046 and VASH2. In addition, we found that VASH2 234	
levels were positively correlated with DESMIN levels in the PEB fraction (Extended Data 235	
Fig.8h-8j), supporting previous data that detyrosinated microtubules are positively correlated 236	
with DESMIN levels in cardiomyocytes5. In summary, our results suggest that MARK4 237	
kinase, through phosphorylation of MAP4 at S914 and S1046, changes MAP4 status to allow 238	
VASH2 access to the polymerized microtubule for its TCP activity.  239	
 240	
To further confirm the causal effect of MARK4 on VASH2 localization, we overexpressed 241	
MARK4 in primary cardiomyocytes, which caused the appearance of pMAP4S1046 (Extended 242	
Data Fig.9a-9c) and giant MAP4 puncta in the cytosol (Extended Data Fig.9d-9e), and led to 243	
increased VASH2 levels in the PEB fraction (Extended Data Fig.9a-9c). By using stimulated 244	
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emission depletion (STED) super-resolution microscopy35, we found a strong co-localization 245	
of VASH2 on the polymerized microtubules in primary cardiomyocytes isolated from wild-246	
type hearts post-MI when compared with the samples isolated from wild-type at baseline 247	
(Extended Data Fig.10a-10b). Total VASH2 levels were comparable between Mark4-/- 248	
cardiomyocytes and Mark4+/+ cells post-MI (Extended Data Fig.10c-10d). However, there 249	
was a significant reduction of VASH2 association with polymerized microtubules in Mark4-/- 250	
compared to wild-type cardiomyocytes (Fig.4f-4g). In conclusion, our results demonstrate 251	
that MARK4 regulates microtubule detyrosination by phosphorylating MAP4 and controlling 252	
VASH2 accessibility to the microtubules (Extended Data Fig.10e).  253	
 254	
Discussion  255	
Detyrosinated microtubules impede contractile function of cardiomyocytes from failing 256	
human hearts7, and targeting the regulatory mechanism controlling microtubule 257	
detyrosination could represent a new inotropic strategy for improving cardiac function. We 258	
show a major role of MARK4 in the alteration of cardiomyocyte contractility through 259	
modulation of microtubule detyrosination in the ischaemic heart. It will be interesting to 260	
examine whether this protective effect of MARK4 inactivation on cardiac function after MI is 261	
sustained in the very long term (several months after MI) without inducing any harmful side 262	
effects, and whether MARK4 inhibition can improve contractile function in the setting of 263	
non-ischaemic heart failure. Furthermore, the marked improvement in relaxation kinetics in 264	
the absence of MARK4 raises the possibility of a potential beneficial effect of MARK4 265	
inhibition in the setting of heart failure with preserved ejection fraction, an increasingly 266	
common cardiac syndrome associated with high morbidity and mortality. The molecular and 267	
structural mechanisms of MARK4 coupled with MAP4 and VASH2/SVBP in modifying 268	
microtubule detyrosination will need to be probed in other settings such as mitosis where 269	
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regulation of detyrosinated microtubules has significant pathophysiological relevance9,36, and 270	
the differential role of other TCPs (e.g. VASH1) will need to be further studied in the future.  271	
  272	
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Figure legends  361	
Fig.1 MARK4 deficiency preserves cardiac function after myocardial infarction without 362	
altering scar size.   363	
a, Real-time PCR of wild-type (WT) heart samples. Baseline (BL): heart without myocardial 364	
infarction (MI). D1, D3, D5, D7: hearts at the relevant days post-MI. n=5 at baseline, n=6 365	
mice per time point at D1, D3 and D5 post-MI, and n=5 mice at D7 post-MI. b, Western blots 366	
of wild-type hearts post-MI. MARK4 in the insoluble (Ins.) cytoskeletal fractions (with 367	
DESMIN as marker), and GAPDH in corresponding soluble (S.) cytosolic fractions are 368	
shown. n=3 mice at each time point. c, Representative immunohistochemical staining of 369	
MARK4 in wild-type mice at baseline or post-MI. Isotype IgG was used as control. Scale 370	
bar=50µm. d-e, Assessment of left ventricular ejection fraction (LVEF) in Mark4-/- mice 371	
(n=7) and their littermate controls (Mark4+/+) (n=7) at baseline, and at week 1 (W1), week 2 372	
(W2), and week 4 (W4) post-MI (d). Scar size at week 4 post-MI (scale bar=2mm) (e). Mean 373	
± s.e.m.; one-way ANOVA test with Bonferroni post-hoc correction (a); two-way ANOVA 374	
with Bonferroni post-hoc correction for multiple comparisons (d); two-tailed unpaired t-test 375	
(e). P values are indicated on the graphs. 376	
 377	
Fig.2 MARK4 expression in cardiomyocytes regulates cardiac contractile function after 378	
myocardial infarction.   379	
a-c, Mark4-/- mice (n=5) and their littermate controls (Mark4+/+, n=5) at day 1 post- 380	
myocardial infarction (MI). Left ventricular ejection fraction (LVEF) (a). Circulating cardiac 381	
troponin I (cTnI) levels (b) and infarct size (scale bar=2mm) (c) at 24 hours (D1) post-MI are 382	
shown. cTnI measurements at Baseline (BL) were used as controls. d, Assessment of LVEF 383	
in chimeric mice (n=8 wild-type recipients of Mark4+/+ bone marrow (BM) donors; n=6 wild-384	
type recipients of Mark4-/- BM donors) at the indicated time points. e, Assessment of LVEF in 385	
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conditional Mark4 deficiency in aMHC-mcm+/-;Mark4fl/fl mice (n=6), with conditional Mark4 386	
deficiency induced by tamoxifen (Tm), at the indicated time points. Tamoxifen-injected 387	
littermate mice, aMHC-mcm+/- and Mark4fl/fl, were used as controls (n=6). f-n, Contractility 388	
assay of single primary cardiomyocytes (CMs) isolated at baseline (BL) or at day 3 post-MI 389	
in the following groups:  Mark4+/+ BL (n=4 mice / n=45 CMs examined over 4 independent 390	
experiments), Mark4-/- BL (n=3 mice / n=45 CMs examined over 3 independent experiments), 391	
Mark4+/+ MI (n=5 mice / n=54 CMs examined over 5 independent experiments), and Mark4-/- 392	
MI (n=6 mice / n=57 CMs examined over 6 independent experiments). Colour denotation of 393	
samples (f). Correlation between LVEF (measured at day 1 post-MI) and sarcomere peak 394	
shortening (g). Sarcomere peak shortening (h). Pooled data of contraction velocity (i) and 395	
relaxation (j) velocity. Violin plots lines at the median and quartiles (h-j). Mean ± s.e.m.; 396	
two-tailed unpaired t-test (a, b, c); two-way ANOVA with Bonferroni post-hoc correction for 397	
multiple comparisons (d, e, h, i, j).  P values are indicated on the graphs. 398	
 399	
Fig.3 MARK4 regulates cardiomyocyte contractility by promoting microtubule 400	
detyrosination.   401	
a-d, Western blots (WBs) of whole heart extraction from mice at day 3 post-myocardial 402	
infarction (MI), in soluble (S.) and insoluble (Ins.) fractions. dTyr-tub: detyrosinated a-403	
tubulin. a-tub: a-tubulin. Representative WBs (a). Ratio of dTyr-tubulin over total a-tubulin 404	
in the following groups: Mark4+/+ MI soluble (n=20), Mark4-/- MI soluble (n=17), Mark4+/+ 405	
MI insoluble (n=8), and Mark4-/- MI insoluble (n=8) (b). Ratio of a-tub in the soluble fraction 406	
over a-tub in the insoluble fraction (n=8 mice per group) (c). Correlation between left 407	
ventricular ejection fraction (LVEF) and ratio of dTyr-tubulin/a-tub, in Mark4-/- (n=9) and 408	
control mice (n=12) (d). e-g, Confocal images of the isolated cardiomyocytes (CMs) at day 3 409	
post-MI. Representative images, scale bar= 20 µm (e). Percentage (%) of dTyr-tub or total a-410	
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tub area per cell (f), and ratio of dTyr-tub/total a-tub (n=3 mice / n=15 CMs per group) (g). h-411	
q, Adenovirus (Adv)-mediated overexpression (o.e.) of TTL in primary cardiomyocytes 412	
isolated from Mark4-/- or control mice at day 3 post-MI, with o.e. of a null as controls (Ctrl). 413	
Contractility assay of single CMs in the following groups: Mark4+/+ MI Adv-Null (n=3 mice / 414	
n=75 CMs examined over 3 independent experiments), Mark4+/+ MI Adv-TTL (n=3 mice / 415	
n=69 CMs examined over 3 independent experiments), Mark4-/- MI Adv-Null  (n=3 mice / 416	
n=74 CMs examined over 3 independent experiments), and Mark4-/- MI Adv-TTL  (n=3 mice 417	
/ n= 73 CMs examined over 3 independent experiments). Colour denotation of samples (h). 418	
Sarcomere peak shortening (i). Pooled data of contraction (j) and relaxation (k) velocity. 419	
Violin plots lines at the median and quartiles (i-k). Mean ± s.e.m.; two-tailed unpaired t-test 420	
(b, c, f, g); two-tailed correlation test (d); two-way ANOVA with Bonferroni post-hoc 421	
correction for multiple comparisons (i, j, k). P values are indicated on the graphs. 422	
 423	
Fig.4 MARK4 controls microtubule detyrosination through MAP4 phosphorylation to 424	
facilitate VASH2 access to microtubules.  425	
a-b, Representative gel image of VASH2/SVBP (3 µM) binding to polymerized microtubules 426	
(MTs) (5 µM) in the presence of different amounts of 4R-MAP4 (1-4 µM) in a microtubule 427	
co-sedimentation assay (a). Quantification of the binding (b). n=3 independent experiments 428	
per group. c-e, Subcellular fractionations on Mark4-/- or control cardiomyocytes (CMs) 429	
isolated post-myocardial infarction (MI). Representative western blots of the fractions from 430	
cytosolic extraction buffer (CEB) or pellet extraction buffer (PEB) derived from the same 431	
experiment (c). Quantification of pMAP4S1046 in CEB, pMAP4S914 in PEB, and VASH2 level 432	
in PEB (n=6 mice per group, blots were processed in parallel) (d). Correlation between 433	
VASH2 level in the PEB fraction and phosphorylated MAP4 (pMAP4) levels (e). f-g, STED 434	
images of VASH2 and a-tubulin (a-tub) in Mark4-/- or control CMs isolated from mice post-435	
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MI. Representative images, scale bar=2 µm (f). Pearson Correlation Coefficient (PCC) of 436	
VASH2 and a-tubulin signals, percentage (%) of VASH2 signals on the polymerized MTs, 437	
and percentage of VASH2 signals off the polymerized MTs, in Mark4+/+ MI group (n=6 mice 438	
/ n=38 CMs examined over 3 independent experiments), and data of Mark4-/- MI group (n=6 439	
mice / n=47 CMs examined over 3 independent experiments) (g). Mean ± s.e.m.; one-way 440	
ANOVA test (b); two-tailed unpaired t-test (d, g); two-tailed correlation test (e). P values are 441	
indicated on the graphs.  442	
	 19	
Methods  443	
Mice  444	
All in vivo experiments using mice were approved by the Home Office, UK, and were 445	
performed under PPL PA4BDF775. All mice were on a C57BL/6 background and housed 446	
under standard temperature (18-23°C) and humidity (40-60%), with 12-hour light/dark cycle. 447	
Mark4-/- mice were kindly provided by Prof Yuguan Shi24 (Barshop Institute), and Mutant 448	
Mouse Resource and Research Center (MMRRC, University of California, Davis); aMHC-449	
mcm+/- Cre mice were originally from the Jackson Laboratory; Mark4fl/fl mice were from 450	
Taconic Biosciences. aMHC-mcm+/- Cre mice were crossed with Mark4fl/fl mice to generate 451	
aMHC-mcm+/- Cre; Mark4fl/fl. The Cre-mediated excision of floxed Mark4 alleles was 452	
induced by treatment with tamoxifen dissolved in corn oil for intraperitoneal injection (i.p.) at 453	
20mg/kg (body weight) per day for 5 constitutive days.  454	
 455	
LAD coronary artery ligation model 456	
Permanent left anterior descending coronary artery ligation was performed on experimental 457	
animals as described22,23 previously with minor modification. Mice, at 8-10 weeks of age, 458	
were anesthetized using ketamine at 100mg/kg (body weight) and xylazine at 10mg/kg (body 459	
weight) via i.p., and then intubated and ventilated with air (supplemented with oxygen) using 460	
a small-animal respirator. A thoracotomy was performed in the fourth left intercostals space. 461	
The left ventricle was visualized and the pericardial sac was ruptured to expose the LAD. The 462	
LAD was permanently ligated using a 7-0 Prolene suture. The suture was passed 463	
approximately 2mm below the tip of the left auricle. Significant colour changes at the 464	
ischaemic area and ECG changes were monitored as an indication of successful coronary 465	
artery occlusion. The thoracotomy was closed with 6-0 Prolene sutures. Sham-operated 466	
animals underwent the same procedure without coronary artery ligation. The endotracheal 467	
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tube was removed once spontaneous respiration resumed, and the mice were placed on a 468	
warm recovery cage maintained at 37 °C until they were completely awake. At the indicated 469	
time points in the experimental timeline, the mice were sacrificed by CO2 asphyxiation, and 470	
the tissues were subsequently harvested for analysis. 471	
 472	
Bone marrow transplants  473	
Eight to ten-week old C57BL/6 mice were maintained overnight with Baytril (Bayer AG) 474	
before irradiation with two doses of 5.5 Gy (separated by 4 hours) followed by reconstitution 475	
with 1×107 sex-matched donor bone marrow cells. Animals were randomly assigned to 476	
receive the Mark4-/- or Mark4+/+ bone marrow. Mice were then maintained on Baytril for a 4-477	
week recovery period before performing LAD ligation. 478	
 479	
Echocardiography 480	
Transthoracic echocardiography was performed on all mice using Vevo 3100 with a MX400 481	
linear array transducer (VisualSonics), 30 MHz. Mice were anesthetized with 2-3% isoflurane 482	
and kept warm on a heated platform (37 °C). The chest hairs were removed using depilatory 483	
cream and a layer of acoustic coupling gel was applied to the thorax. After alignment in the 484	
transverse B-mode with the papillary muscles, cardiac function was measured on M-mode 485	
images. Echocardiography data were collected by using VisualSonics Vevo 3100, and 486	
analyzed by using Vevo LAB3.1.1.   487	
 488	
Histological analysis 489	
Whole hearts were excised at different time point after LAD ligation, rinsed in PBS and fixed 490	
with 4% PFA overnight at 4°C. Fixed tissues were thoroughly washed in PBS, and then 491	
sinked in 30% sucrose. Tissues were embedded and sectioned by a cryostat into 10μm thick 492	
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slices, which started at the apex and ended at the suture ligation site. Masson’s trichrome 493	
staining was performed to determine scar size. Scar size (in %) was calculated as total infarct 494	
circumference divided by total left ventricle circumference. Some hearts were excised at 24 495	
hours post-MI and quickly sliced into four 1.0 mm thick sections perpendicular to the long 496	
axis of the heart. The sections were then incubated with 1% triphenyltetrazolium chloride 497	
(TTC, Sigma) for 15 minutes at 37°C and then digitally photographed. For infarct size at 24 498	
hours post-MI, TTC-stained area, and TTC-negative staining area (infarcted myocardium) 499	
were measured using ImageJ (v2.0). Myocardial infarct size was expressed as a percentage of 500	
the total left ventricle area. Images were obtained by using Leica DM6000 B Microscope, 501	
collected by using LAS AF software (2.4.0 build 6254), and analyzed by using ImageJ (v2.0) 502	
analyze tools. 503	
 504	
Tissue immunohistochemistry 505	
Whole hearts were excised, quickly washed in PBS, and flash frozen. Tissues were then 506	
embedded and cryo-sectioned.  Slices were fixed in pre-chilled methanol for 10 minutes at -507	
20℃. After washing with PBST (0.1% tween-20 in 1×PBS), slices were incubated with 3% 508	
H2O2 (in PBS) for 10 minutes, and then with blocking buffer (5% BSA in PBST) for 1 hour at 509	
room temperature. The primary antibody against MARK4 (Abcam, ab124267, used at 1:200), 510	
or rabbit IgG isotype control (Novus Biologicals, NB810-56910, used at 1:1000)  was used 511	
for overnight at 4℃. Extensive washing steps were performed to remove nonspecific binding 512	
antibody. Slices were incubated with the biotinylated secondary antibody (Abcam, ab6720, 513	
used at 1:800) for 1 hour at room temperature. Reagents A and B from Avidin-Biotin 514	
Complex kit (VECTOR, PK-4000) were diluted and added to the slides. The slides were 515	
stained with ImmPACT DAB peroxidase substrate (VECTOR, SK-4105), and counterstained 516	
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with hematoxylin. Images were obtained by using Leica DM6000 B Microscope, collected by 517	
using LAS AF software (2.4.0 build 6254), and analyzed by using ImageJ (v2.0) analyze tools. 518	
 519	
Microtubule co-sedimentation assay 520	
Lyophilized porcine brain tubulin (T240) was purchased from Cytoskeleton, Inc (Denver, 521	
USA). Recombinant proteins of 4R-MAP4 and VASH2/SVBP were previously described12,34. 522	
The desiccated tubulin was reconstituted in the microtubule polymerization buffer to 10 523	
mg/mL. To generate polymerized microtubules, tubulin was diluted to 2 mg/mL in the 524	
polymerization buffer (80mM K-PIPES, pH 6.8, 1mM MgCl2, 1mM EGTA and 1mM DTT), 525	
supplemented with 5% glycerol and 1mM GTP at 37°C for 30 minutes, and then stabilized by 526	
incubating with 2.5 μM taxol at 37°C for 15 minutes. The taxol stabilized MTs were 527	
centrifuged over cushion buffer (polymerization buffer with 40% glycerol) at 131,700g at 528	
37°C for 15 minutes to remove the free tubulin. The pellet was suspended in the 529	
polymerization buffer with 1 μM taxol. Taxol influenced the association of 4R-MAP4 with 530	
the MTs in our assay. 4R-MAP4 association was facilitated when taxol was completely 531	
excluded from the buffer. The MTs without taxol were susceptible to depolymerisation if 532	
stored at room temperature. In these conditions, the polymerized microtubules were 533	
maintained at 37°C throughout the experiment. For the co-sedimentation assay, the MTs were 534	
mixed with various concentrations of 4R-MAP4 (1-6 µM) and VASH2/SVBP (1-4 µM) in the 535	
polymerization buffer. In the competition experiments, the MTs were incubated with 536	
specified 4R-MAP4 concentrations (1-4 µM) for 10 minutes, followed by addition of constant 537	
amount of VASH2/SVBP (3 µM) with further incubation of 10 minutes. Subsequently, the 538	
reaction mixture was centrifuged in TLA120.2 rotor at 55,000 rpm for 15 minutes. The pellet 539	
fraction containing the MTs and bound proteins was resuspended in the loading buffer. The 540	
samples were loaded on 10 % SDS-PAGE gel and stained with Colloidal Coomassie blue dye 541	
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(ThermoFisher). The experiments were repeated at least 3 times. The band intensities were 542	
analyzed using ImageJ (v2.0). 	543	
 544	
Murine cardiomyocyte isolation  545	
Cardiomyocytes preparation was accomplished as previously described28. In brief, mice were 546	
anesthetized, and the chest was opened to expose the heart. Descending aorta was cut, and the 547	
heart was immediately flushed by injection of 7 mL EDTA buffer into the right ventricle. 548	
Ascending aorta was clamped, and the heart was transferred to a 60 mm dish containing fresh 549	
EDTA buffer. Digestion was achieved by sequential injection of 10 mL EDTA buffer (NaCl, 550	
130mM; KCl, 5mM; NaH2PO4, 0.5mM; HEPES, 10mM; Glucose, 10mM; BDM, 10mM; 551	
Taurine, 10mM; EDTA, 5mM; pH to 7.8), 3 mL perfusion buffer (NaCl, 130mM; KCl, 5mM; 552	
NaH2PO4, 0.5mM; HEPES, 10mM; Glucose, 10mM; BDM, 10mM; Taurine, 10mM; MgCl2, 553	
1mM; pH to 7.8), and 30 to 50 mL collagenase buffer (Collagenase 2, 0.5mg/mL; 554	
Collagenase 4, 0.5mg/mL; Protease XIV, 0.05mg/mL; made fresh and diluted in perfusion 555	
buffer) into the left ventricle. Left ventricle was then separated and gently pulled into 1 mm 556	
pieces using forceps.	 Cellular dissociation was completed by gentle trituration, and enzyme 557	
activity was inhibited by addition of 5 mL stop buffer (Perfusion buffer containing 5% sterile 558	
FBS). Cell suspension was passed through a 100-μm filter. Cells underwent 4 sequential 559	
rounds of gravity settling, using 3 intermediate calcium reintroduction buffers (Buffer 1: 75% 560	
Perfusion buffer with 25% culture media; Buffer 2: 50% Perfusion buffer with 50% culture 561	
media; Buffer 3: 25% Perfusion buffer with 75% culture media; Culture media comprise 0.1% 562	
BSA, 1% ITS, 10mM BDM, 1% CD lipid and 5% Penicillin / Streptomycin in M199) to 563	
gradually restore calcium concentration to physiological levels. 564	
 565	
Primary cardiomyocyte culture and adenoviral transduction  566	
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Adenoviral vectors including pAdeno-SV40-GFP-Blank vector (Adv-null), pAdeno-Ttl-567	
SV40-GFP vector (Adv-Ttl) (NM_027192.2) and pAdeno-Mark4-SV40-GFP vector (Adv-568	
Mark4) (NM_172279.1) were purchased from Applied Biological Materials Inc. Adenoviral 569	
vector pAV[shRNA]-EGFP-U6>mMap4 (shRNA Map4 target sequence: 570	
AGAGTGGACTATCCGGATTAT), adenoviral vector pAV[shRNA]-EGFP-U6>mVash2 571	
(shRNA Vash2 target sequence: GAGAATCCTTGCCTATCAAAT), and adenoviral vector 572	
pAV[shRNA]-EGFP-U6>Scramble were purchased from VectorBuilder. 6 well plates or 573	
coverslips were coated with laminin at a final concentration of 5 μg/mL in PBS overnight at 574	
4°C. The wells were washed and air-dried for 10 minutes before plating cells. After collecting 575	
the cells by gravity settling and calcium re-introduction, the final myocyte pellets were re-576	
suspended in 2 mL culture media and 2 mL pre-equilibrated plating media  (0.1% FBS, 577	
10mM BDM, and 5% Penicillin / Streptomycin in M199) for culture. After one-hour 578	
incubation, cell media was changed with pre-equilibrated culture media and adenovirus 579	
vectors were administered at 5*106 pfu/mL. After co-culture with virus for 8 hours, fresh 580	
culture media was used to wash and replace the old culture media with virus. Cells were 581	
either subjected to contractility assay and western blotting immediately after media change (in 582	
the experiments of overexpression of TTL), or collected at 48 hours after transduction (in the 583	
experiments of overexpression of Mark4, shRNA Map4 and shRNA Vash2) for the 584	
subsequent assays.  585	
 586	
Cardiomyocyte contractility assay 587	
Sarcomere shortening and relaxation were measured in freshly isolated left ventricular 588	
cardiomyocytes of murine hearts using the integrated IonOptix contractility/photometry 589	
system. Cardiomyocytes were maintained in normal Tyrode’s solution (NaCl, 140mM; 590	
MgCl2, 0.5 mM; NaH2PO4, 0.33mM; HEPES, 5mM; glucose, 5.5mM; CaCl2, 1mM; KCl, 591	
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5mM; NaOH, pH to 7.4) at room temperature, electrically stimulated at 2 Hz using a field 592	
stimulator, and changes in sarcomere length were recorded. Basal and peak sarcomere length, 593	
maximum departure/return velocities and time to peak were measured. All measurements 594	
were performed at room temperature. For PTL experiments, cardiomyocytes were treated 595	
with 10 μM PTL (Sigma P0667) or vehicle at room temperature in normal Tyrode’s solution 596	
for 1 hour before contractility measurements, and the vehicle dimethyl sulfoxide (DMSO) 597	
diluted in the same way was applied as control. All measurements were performed at room 598	
temperature within 4 hours. Data were collected and analyzed by using IonWizard 7.4. 599	
 600	
Calcium measurement 601	
Measurement of intracellular calcium was performed in freshly isolated left ventricular 602	
cardiomyocytes using integrated IonOptix contractility/photometry system. Cardiomyocytes 603	
were loaded with 1 μM Fura-2-AM for 20 minutes (protected from light), and then washed to 604	
allow de-esterification for 20 minutes. Cells were then rinsed with a normal Tyrode’s 605	
Solution. Cells were stimulated at 2 Hz using a field stimulator with dual excitation (at 360 606	
and 380 nm), and emission light was collected at 510 nm. Changes in calcium transients were 607	
recorded using IonOptix software. All the cells analyzed were beating. All measurements 608	
were performed at room temperature within 4 hours. Data were collected and analyzed by 609	
using IonWizard 7.4 610	
 611	
Immunofluorescence and image acquirement    612	
Cardiomyocytes were fixed with pre-chilled methanol for 10 minutes, then washed twice 613	
using PBST (0.1% tween-20 in 1×PBS) with 5 minutes intervals. Cells were blocked for 1 614	
hour at room temperature with blocking buffer (5% BSA in PBST) and incubated with 615	
primary antibodies overnight at 4°C. The primary antibodies were: Detyrosinated α-tubulin 616	
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(Abcam, ab48389, used at 1:200), α-tubulin (CST, 3873S, used at 1:200), MARK4 (Abcam, 617	
ab124267, used at 1:200), APC anti-mouse CD45 (BioLegend, 103112, used at 1:200) and 618	
rabbit IgG isotype control (Novus Biologicals, NB810-56910, used at 1:2000). The cells were 619	
then washed with PBST and incubated with secondary antibody for 1 hour at room 620	
temperature. The secondary antibodies were: AF488 donkey anti-rabbit IgG (Invitrogen, 621	
A21206, used at 1:200), AF647 goat anti-mouse IgG (Invitrogen, A21236, used at 1:200), 622	
AF647 goat anti-rat IgG (Invitrogen, A21247, used at 1:200). DAPI (Sigma, 10236276001, 623	
used at 1:1000) was used. Confocal images were obtained by Leica SP5 Confocal Laser 624	
Scanning Microscope, collected by LAS AF software (2.7.3.9723), and analyzed by ImageJ 625	
(v2.0) analyze tools. 626	
 627	
STED imaging and image analysis 628	
Cardiomyocytes on coverslips were fixed with 100% methanol for 15 minutes at room 629	
temperature and then washed three times with PBS (5 minutes intervals). Cells were blocked	630	
with buffer (5% BSA and 0.2% TX-100 in PBS) for 30 minutes, then incubated with primary 631	
antibodies (diluted in blocking buffer) overnight at 4°C. The primary antibodies were VASH2 632	
(Abcam, ab224723, used at 1:200), MAP4 (Abcam, ab245578, used at 1:200) and α-tubulin 633	
(CST, 3873S, used at 1:200). The cells were washed three times using wash buffer (0.05% 634	
TX-100 in PBS) at room temperature, then incubated with the secondary antibody for 1 hour 635	
at room temperature. The secondary antibodies were: Atto 594 goat anti-Rabbit IgG (Sigma, 636	
77671, used at 1:500), and Atto 647N goat anti-mouse IgG (Sigma, 50185, used at 1:500). 637	
Cells were then washed three times in wash buffer. Cells were fixed (3% Paraformaldehyde 638	
and 0.1% glutaraldehyde diluted in PBS) followed by three washes in PBS. The coverslips 639	
were then mounted on the slide.  640	
 641	
	 27	
STED imaging was carried out on a custom multicolour system with three pulsed excitation 642	
lines, one fixed depletion line, fast 16 kHz beam scanning and gated detection centered 643	
around an Olympus IX83 microscope base. This system uses identical hardware, and a closely 644	
matched optical arrangement, to the system previously published by Bottanelli and co-645	
workers35. In brief, two-colour STED imaging was performed sequentially. Images were 646	
acquired with a 100X oil immersion objective lens (Olympus, UPLSAPO 100XO/PSF). 647	
Fields of view between 23 and 27 µm2 were imaged with a 1024 x 1024 image format and an 648	
approximately 20 nm pixel size. Excitation powers were between 15 and 30 µW at the 649	
microscope side port while STED depletion power was approximately 120 mW at the 650	
microscope side port. Fast, 16 kHz, unidirectional beam scanning with blanking was 651	
employed to minimize light exposure. Each line of an image was scanned 850 times resulting 652	
in an image acquisition time of approximately 54 seconds per colour. STED image data were 653	
collected with a custom program written in National Instrument (NI) LabVIEW 2014 64-bit, 654	
NI FPGA Module and NI Vision Development Module. 655	
 656	
MAP4 oligomerized puncta (with diameter longer than 400 nm) were measured and 657	
calculated using ImageJ (v2.0). The number of puncta was normalized against the cell area on 658	
each image.  659	
 660	
For the acquired images, a dynamic thresholding algorithm was used for the image analysis. 661	
Images were converted into HSV colour images (C) with information of Hue (h), Saturation 662	
(s), and Value (v). C (I, j) was assumed as a non-background image pixel, N was the total 663	
number of non-background image pixels. The average of all the non-background image pixels 664	
was calculated as: k = (∑ ∑ 𝐶(𝑖, 𝑗))	/𝑁!"#$%&#$ . The following three thresholds were applied to 665	
discriminate signals: h = [0,180]; s = [0,43]; v = [k+30,220]. The Gaussian filter (𝑓(𝑥) =666	
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$
'()!
e*
"!#$!
!%! 	), a 2-D convolution operator, was used to remove noise. For the VASH2 signals, 667	
the Gaussian filter with the kernel of 3*3 was used for image denoising. For the linear 668	
microtubule signals, the Gaussian filter with the kernel of 5*5 was used for image denoising 669	
when k >= 35, and kernel of 3*3 was applied when k<35.  The total numbers of VASH2 (v) 670	
and TUBULIN (t) pixels were calculated. The total number of the overlapping image pixels 671	
(o) between VASH2 and TUBULIN was calculated as VASH2 signals on the microtubules, 672	
and (1-o)/v was calculated as VASH2 signals off the microtubules. The Pearson correlation 673	
coefficient (PCC) (𝜌+,- =
./0(+,-)
3&3'
 ) between VASH2 signals and TUBULIN signals was 674	
calculated.  Automatic image processing was coded using a custom algorithm in python 3.7.8.  675	
 676	
Subcellular fractionations of the primary cardiomyocytes 677	
Subcellular fractionations on primary cardiomyocytes were performed according to 678	
manufacturer’s instructions (Pierce, 87790). Briefly, cells were incubated with Cytoplasmic 679	
Extraction Buffer (CEB) which selectively permeabilizes the cell membrane for 10 minutes at 680	
4°C with gentle mixing. Cells were centrifuged for 5 minutes at 500g and supernatants were 681	
collected. The cytoskeletal binding proteins were isolated in the Pellet Extraction Buffer 682	
(PEB).  683	
 684	
Subcellular fractionations of primary cardiomyocytes were also obtained using a conventional 685	
method as the following: Primary murine cardiomyocytes were isolated and homogenized in 686	
pre-warmed (37°C) microtubule stabilizing buffer (MTSB buffer: PIPES, 80mM; MgCl2, 687	
1mM; EGTA, 1mM; 0.5% Triton X-100; 10% glycerol; GTP, 0.5mM;	 HaltTm Protease 688	
Inhibitor Cocktail from Thermo Fisher Scientific 1862209; pH to 6.8) using Dounce 689	
homogenizer. The homogenates were centrifuged at 100,000g for 15 minutes at room 690	
temperature. The supernatants were collected as F1 (free tubulin fraction), and the pellets 691	
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were dissolved in the microtubule destabilizing buffer (MTDB buffer: Tris-HCl, 20mM; NaCl, 692	
150mM; 1% Triton X-100; CaCl2, 10mM;	 HaltTm Protease Inhibitor Cocktail from Thermo 693	
Fisher Scientific 1862209; pH to 7.4) for further incubation on ice for one hour to 694	
depolymerize the microtubules. The dissolved lysates were centrifuged at 12,000g for 15 695	
minutes at 4°C. The pellets were incubated with 150 units micrococcal nuclease (100 units/μL, 696	
Thermo Fisher Scientific, 88216) in the MTDB buffer for 15 minutes at room temperature, 697	
and then centrifuged at 12,000g for 5 minutes at 4°C to remove the nuclear. The collected 698	
pellets were dissolved in 2xSDS buffer (4% SDS; 20% glycerol; Tris-HCl, 0.25M; pH to 6.5). 699	
The dissolved lysates were then centrifuged at 14,000g for 5 minutes at 4°C.  The 700	
supernatants were collected as F2 (extraction from the stable pellet fraction), and the residual 701	
pellets were kept.   702	
 703	
Western blotting 704	
The heart tissues were grounded thoroughly with a mortar and pestled in liquid nitrogen. 705	
Tissue powder was lysed using Triton lysis buffer [20mM Tris-HCl, pH to 7.5; 150mM NaCl; 706	
1mM Na2EDTA; 1mM EGTA; 1% Triton; 1mM Na3VO4; 5mM NaF; protease inhibitor 707	
cocktail (ThermoFisher, 1862209)]. The supernatant (soluble fraction) was collected, and the 708	
pellets (insoluble fraction) were dissolved in 8M Urea (Fig.1b; Fig.3a; Fig.3d; n=12 mice in 709	
Mark4+/+ MI group, and n=9 mice in Mark4-/- MI group used for Fig.3b-3c). For some 710	
experiments (n=8 mice per group used for Fig.3b-3c), heart tissues were homogenized in the 711	
lysis buffer [0.1M PIPES pH to 6.8; 2mM EGTA; 0.1mM EDTA; 0.5 mM MgCl2; 20% 712	
glycerol; 0.1% Triton X-100; protease inhibitor cocktail (ThermoFisher, 1862209)], and 713	
incubated for 30 minutes at 37°C. After centrifugation (21,100g for 5 minutes), the 714	
supernantants were collected as soluble fraction, and the pellets were dissolved in the buffer 715	
[RIPA buffer (CST, 9806); 0.8% SDS; and protease inhibitor cocktail (ThermoFisher, 716	
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1862209)] and collected as insoluble fraction. Protein concentration was determined by 717	
BCATM protein assay kit (ThermoFisher, 23235). Molecular weight markers (ThermoFisher, 718	
LC5603, LC5925) were used. Supernatant samples were prepared in NuPAGE LDS sample 719	
buffer (Invitrogen) and run on NuPAGE 4-12% Bis-Tris gels (Invitrogen). Pellet samples 720	
were prepared in Tris-Glycine SDS sample buffer (Invitrogen) and run on Novex 4-20% Tris-721	
Glycine gels (Invitrogen). All samples were blotted onto a PVDF membrane after 722	
electrophoresis. The following primary antibodies were used in the experiments: MARK4 723	
(CST, 4834S, used at 1:1000), GAPDH (CST, 5174S, used at 1:1000), DESMIN (R&D, 724	
AF3844, used at 1:1000), detyrosinated α-tubulin (Abcam, ab48389, used at 1:200), 725	
polyglutamylated a-Tubulin (AdipoGen, AG-20B-0020-C100, used at 1:1000), acetylated a-726	
Tubulin (Santa Cruz Biotechnology, sc23950, used at 1:1000), α-tubulin (CST, 3873S, used 727	
at 1:200). After antibody detections, membranes were revealed with ECL. Quantification of 728	
western blot band was analyzed by ImageJ (v2.0). 729	
 730	
For the fractionation assay, equal amounts of total protein (20 µg) from each fraction were 731	
used for western blot. DCTM protein assay kit (Bio-Rad, 5000111) was used to measure 732	
protein concentration. Across different gels, equal amount of molecular weight marker 733	
(ThermoFisher, LC5603) was loaded in each gel. Samples were run on NuPAGE 4-12% Bis-734	
Tris gels (Invitrogen) and blotted onto a PVDF membrane.  735	
 736	
Some samples of CEB fraction from fractionation assay were prepared for native gel running 737	
as the following. Samples were processed in Tris-Glycine native sample buffer 738	
(ThermoFisher, LC2673) before loading without heating and adding any reducing reagent. 739	
Samples were loaded in 3-8% NuPAGE Tris-Acetate gel (ThermoFisher, EA0375BOX) for 740	
electrophoresis in Tris-Glycine native running buffer (Tris Base, 25mM; Glycine, 192mM; pH 741	
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to 8.3). Native molecular marker (ThermoFisher, LC0725) was used. After electrophoresis, 742	
proteins were transferred to PVDF membrane by transfer buffer (Bicine, 25mM; Bis-Tris, 743	
25mM; EDTA, 1mM; pH to 7.2).  744	
 745	
Some samples from fractionation assay were prepared with denaturing treatment by adding 746	
urea. Urea (0 M, 2 M, 4 M or 8 M) was added to the samples as indicated. Micro BCATM 747	
protein assay kit (ThermoFisher, 23235) was used to measure protein concentrations if the 748	
samples were added with Urea. Samples were then processed in Tris-Glycine SDS sample 749	
buffer (ThermoFisher, LC2676) and reducing reagent (10% 2-mercaptoethanol). 4-20% Tris-750	
Glycine gel (ThermoFisher, EC6026BOX) was used for electrophoresis in Tris-Glycine SDS 751	
running buffer (Tris Base, 25 mM; glycine, 192 mM; 0.1% SDS; pH to 8.3).  After 752	
electrophoresis, proteins were transferred to PVDF membrane by transfer buffer (Tris Base, 753	
12 mM; glycine, 96 mM; pH to 8.3).  754	
 755	
The primary antibodies used for fractionation assays were: Detyrosinated α-tubulin (Abcam, 756	
ab48389, used at 1:1000), α-tubulin (CST, 3873S, used at 1:1000), TTL (Proteintech, 13618-757	
1-AP, used at 1:1000), VASH1 (Abcam, ab199732, used at 1:1000), VASH2 (Abcam, 758	
ab224723, used at 1:1000), MAP4 (phospho S1073) (Abnova, PAB15916, used at 1:1000), 759	
MAP4 (Abcam, ab245578, used at 1:1000), MAP4 (phospho S941) (Abcam, ab56087, used at 760	
1:1000), GAPDH (CST, 5174S,used at 1:1000), DESMIN (R&D, AF3844, used at 1:1000). 761	
Membranes were revealed with ECL. Quantification of western blot band was performed 762	
using ImageJ (v2.0). The band density was normalized in two steps: 1). The density of the 763	
targeted band was first normalized against the density of the loading molecular weight marker 764	
band (Norm 1). 2). The value of Norm 1 was internally normalized against the average value 765	
of Norm1 of the control group  (Norm2). The finalized value (Norm 2) was used to compare 766	
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the fold changes against the value of control groups across different gels. DESMIN was used 767	
as marker for the pellet fraction, and GAPDH was used as a marker for the cytosolic fraction. 768	
Coomassie blue stained gels loaded with the same amounts of proteins as used in western 769	
blotting experiments, or Ponceau S stained membranes after the transferring step were used to 770	
confirm the equal loading. All the immunoblots, gels and membranes associated with the data 771	
presented in the Figures and Extended Data Figures are provided (Supplementary Figure 1). 772	
 773	
Heart tissue digestion and flow cytometry 774	
Hearts were collected and the left ventricle was isolated, minced with fine scissors, and 775	
subjected to enzymatic digestion solution [RPMI 1640, collagenase D (0.2 mg/mL, Roche), 776	
dispase (1 U/mL, StemcellTM Technologies) and DNase I (0.2 mg/mL, Sigma)] for 45 777	
minutes at 37°C. Cells were collected, filtered through 40-μm nylon mesh, and washed with 778	
PBS with 2.5% vol/vol fetal bovine serum. Cell suspensions were incubated with Zombie 779	
Aqua™ Fixable Viability Kit (Biolegend, 423102, used at 1:1000) for 20 minutes at room 780	
temperature then washed with PBS. Cells were then stained with fluorescently labelled anti-781	
mouse antibodies comprised of APC anti-mouse CD45  (Biolegend, 103112, used at 1:100), 782	
AF488 anti-mouse CD11b (Biolegend, 101217, used at 1:100), Pacific blue anti-mouse Ly6G 783	
(Biolegend, 127612, used at 1:100), PE anti-mouse F4/80 (Biolegend, 123110, used at 1:100), 784	
PECY7 anti-mouse CD11c (Biolegend, 117318, used at 1:100), Brilliant Violet 605 anti-785	
mouse CD3 (Biolegend, 100237, used at 1:100) and FITC anti-mouse CD19 (Biolegend, 786	
553785, used at 1:100), diluted in staining buffer for 30 minutes at 4°C	 in the presence of 787	
24G2 Fc receptor blocker (obtained from Division of Immunology, Department of Pathology, 788	
University of Cambridge), prior to extensive washing. The cytometric acquisition was 789	
performed on a LSR II Fortessa (BD biosciences). Cell analysis was done using BD 790	
FACSDiva Software 6.0 and FlowJo software (v10). 791	
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 792	
Real-time PCR  793	
For gene expression analysis, RNA from heart tissues or separated cardiomoycytes was 794	
isolated using an RNAeasy mini kit (Qiagen). Reverse transcription was performed using a 795	
QuantiTect reverse transcription kit (Qiagen). qRT-PCR was performed with SYBR Green 796	
qPCR mix (Eurogentec) using the Roche LightCycler 480II. Primer sequences are as follows: 797	
Mark4 (For. 5’-	 GGACACGCATGGCACATTG-3’; Rev. 5’-798	
GCAGGAAGCGATAGAGTTCCG-3’); Vash2 (For. 5’-GCCTTCCTGGCTAAGCCTTC-3’; 799	
Rev. 5’-CCCTGTGTGGTTGTATTGTAGAG-3’); Hprt (For. 5’-800	
TCAGTCAACGGGGGACATAAA-3’; Rev. 5’-GGGGCTGTACTGCTTAACCAG-3’); 801	
Rpl4 (For. 5’-CCGTCCCCTCATATCGGTGTA-3’; Rev. 5’-802	
GCATAGGGCTGTCTGTTGTTTTT-3’); Rpl13a (For. 5’-803	
AGCCTACCAGAAAGTTTGCTTAC-3’; Rev. 5’-GCTTCTTCTTCCGATAGTGCATC-3’). 804	
The average of three housekeeping genes (Hprt, Rpl4, and Rpl13a) was used as reference for 805	
qPCR gene expression analysis.  806	
 807	
Measurement of cTnI and inflammatory cytokines 808	
Serum was collected within 24 hours post-MI or at day 3 post-MI. Measurements of cardiac 809	
injury biomarker (collected within 24h) and cytokines (collected at day 3 Post-MI) were 810	
performed by core biochemical assay laboratory of Cambridge University Hospitals. 811	
 812	
Statistics and Reproducibility 813	
All values in the text and figures are presented as mean ± s.e.m. of independent experiments 814	
with given n sizes. Statistical analysis was performed with Prism 7.05 (GraphPad) and Excel 815	
(Microsoft Excel 2102). Violin plots were created with Prism 9.1.0 (216) (GraphPad). Data 816	
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were tested for normality using a Kolmogorov-Smirnov test. Group comparisions were 817	
analyzed using two-tailed analyses. Comparisons of 3 groups or more were analyzed using 818	
one-way (one variable) or two-way ANOVA (two variables) followed by the Bonferroni post-819	
hoc correction for multiple comparisons when appropriate. P<0.05 was considered 820	
statistically significant. 821	
 822	
Fig.1b, Fig.1c, Fig.3a, Extended Data Fig.2a, Extended Data Fig.5a, Extended Data Fig.7b, 823	
and Extended Data Fig.8a-8b are representative figures for 3 independent experiments. 824	
Extended Data Fig.8e-8g are representative figures for 2 independent experiments. 825	
 826	
Data availability 827	
All the associated raw data presented in this paper are available from the corresponding 828	
author upon request. Source data are provided with this paper. 829	
 830	
Code availability 831	
Custom codes used in this paper are available on Github (http://github.com).  832	
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Extended Data Fig. 1. Timeline of experimental design. 881	
a, Timeline of experimental design for Fig. 1d and 1e. Investigation of the effect of total 882	
MARK4 deficiency on cardiac function using the model of left anterior descending (LAD) 883	
coronary artery ligation model to induce myocardial infarction (MI). Echocardiography 884	
(Echo) and histological analysis at the indicated time points. b, Timeline of experimental 885	
design for Fig. 2a, 2b, and 2c. Investigation of the effect of total MARK4 deficiency on 886	
cardiac function at 24 hours post-MI. Echocardiography, circulating cardiac troponin (cTnI), 887	
and histological analyses were performed at the indicated time point. c, Timeline of 888	
experimental design for Fig. 2d. Investigation of the effect of MARK4 expression in 889	
haematopoietic cells on cardiac function using the LAD ligation model. BM: bone marrow. 890	
BMT: bone marrow transplantation. Echocardiography analysis was performed at the 891	
indicated time points. d, Timeline of experimental design for Fig. 2e. Investigation of the 892	
effect of MARK4 expression in cardiomyocytes on cardiac function using the LAD ligation 893	
model. Tm: tamoxifen. Mark4cKO: conditional Mark4 knock-out mice. Echocardiography 894	
analysis was performed at the indicated time points.  895	
 896	
Extended Data Fig. 2. MARK4 expression, a-tubulin post-translational modifications, 897	
and changes in the inflammatory response post-myocardial infarction.   898	
a, Representative confocal images of primary cardiomyocytes (CMs) isolated from Mark4-/- or 899	
control mice at baseline (BL) or at day 3 post-MI (MI), scale bar= 20 µm. b-c, Levels of pro-900	
inflammatory cytokines at day 3 post-MI (n=6 per group) (b). Left ventricular ejection 901	
fraction (LVEF) at day 3 post-MI (n=4 per group) (c). d-e, Western blots (WBs) of 902	
detyrosinated a-tubulin (dTyr-tub) in cell lysates of CMs isolated from wild-type mice at day 903	
3 post-MI or post-sham surgery (S), with the lysates of the remaining cells from the same 904	
hearts used as control. Representative WBs (d). Ratio of dTyr-tubulin over total a-tubulin 905	
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quantified using western blot data from biologically independent samples (S group: n=4 mice; 906	
MI group: n=5 mice) (e). f-g, Western blots of cell lysates from the isolated cardiomyocytes 907	
of Mark4-/- or control mice at day 3 post-MI, to detect detyrosinated a-tubulin (dTyr-tub), 908	
polyglutamylated a-tubulin (Polyglu-tub), acetylated a-tubulin (Ace-tub), and  a–tubulin (a-909	
tub). Representative images (f). Ratio of dTyr-tub, or polyglu-tub, or ace-tub over total a-910	
tubulin quantified using western blot data from biologically independent samples (n=3 mice 911	
per group) (g). The box bounds represent the 25th and 75th percentiles, the middle line shows 912	
the median, and the whiskers show the minimum and maximum (b). Mean±s.e.m.; two-tailed 913	
unpaired t-test (c, e, g). P values are indicated on the graphs.  914	
 915	
Extended Data Fig. 3. Validation of the murine models for MARK4 selective expression 916	
in either haematopoietic cells or cardiomyocytes.   917	
a-b, Confirmation of MARK4 deficiency in CD45+ cells of chimeric wild-type mice 918	
reconstituted with bone marrow (BM) cells from Mark4-/- mice(strategy in Extended Data 919	
Fig.1c). Representative image with arrows pointing to CD45+ cells in the infarct area, scale 920	
bar= 20 µm (a). Quantification of percentage of MARK4 positive cells (green) within CD45+ 921	
cells (red) (n=3 mice per group) (b). c, Confirmation of Mark4 deletion in cardiomyocytes 922	
(strategy in Extended Data Fig.1d). Real-time PCR of Mark4 level from primary 923	
cardiomyocytes isolated from aMHC-mcm+/-;Mark4fl/fl  (n=4) and control mice (n=3) at day 7 924	
post the last tamoxifen injection. d-e, Assessment of left ventricular ejection fraction (LVEF) 925	
of a different batch (from Fig. 2e) of conditional Mark4 deficiency in cardiomyocytes 926	
(Mark4cKO) and control mice (n=6 per group) at day 1 post-myocardial infarction (MI) (d). 927	
Infarct size at 24 hours post-myocardial infarction (scale bar=2mm) (e). Mean±s.e.m.; two-928	
tailed unpaired t-test (b, c, d, e). P values are indicated on the graphs. 929	
 930	
39	
Extended Data Fig. 4.  The effect of MARK4 deficiency on sarcomere length, peak 931	
shortening, velocity, and calcium transients in cardiomyocytes before and after 932	
myocardial infarction.  933	
a-f, Contractility assay of single primary cardiomyocytes (CMs) isolated at baseline (BL) or934	
at day 3 post-myocardial infarction (MI) from the following groups: Mark4+/+ BL (n=4 mice / 935	
n=45 CMs examined over 4 independent experiments), Mark4-/- BL (n=3 mice / n=45 CMs 936	
examined over 3 independent experiments), Mark4+/+ MI (n=5 mice / n=54 CMs examined 937	
over 5 independent experiments), and Mark4-/- MI (n=6 independent mice / n=57 CMs 938	
examined over 6 independent experiments). Colour denotation of samples (a). Resting 939	
sarcomere length (SL) (b). Average sarcomere shortening traces were compared (c-d). 940	
Average velocity traces (dSL/dT) (e-f).  g-m, Calcium influx assay on single CMs isolated 941	
from Mark4-/- or control mice at baseline or at day 3 post- MI in the following groups: 942	
Mark4+/+ BL group (n=2 mice / n=34 CMs examined over 2 independent experiments), 943	
Mark4-/- BL groups (n=2 mice / n=33 CMs examined over 2 independent experiments), 944	
Mark4+/+ MI group (n=4 mice / n=65 CMs examined over 4 independent experiments), 945	
Mark4-/- MI groups (n=3 mice / n=58 CMs examined over 3 independent experiments). Basal 946	
Ca2+ level (g). Amplitude level of Ca2+ transient (h). Ca2+ release speed during contraction (i). 947	
Ca2+ reuptake speed during contraction (j). Ca2+ elevation time (k).  Ca2+ reuptake time (l). 948	
Traces of Ca2+ kinetic curves (m). The box bounds represent the 25th and 75th percentiles, the 949	
middle line shows the median, and the whiskers show the minimum and maximum (b, g-l). 950	
Mean ± s.e.m.; two-way ANOVA with Bonferroni post-hoc correction for multiple 951	
comparisons (b, g-l). P values are indicated on the graphs. 952	
953	
Extended Data Fig. 5. The effect of TTL overexpression, or PTL treatment, on 954	
contractility of Mark4-/- cardiomyocytes after myocardial infarction. 955	
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a-i, Adenovirus (Adv)-mediated overexpression (o.e.) of Tubulin Tyrosine Ligase (TTL) in 956	
cardiomyocytes isolated from Mark4-/- or control Mark4+/+ mice at day 3 post-myocardial 957	
infarction (MI), with o.e. of a null as control (Ctrl). Representative western blot (a). 958	
Contractility assay of single CMs with o.e. in the following groups: Mark4+/+ MI Adv-Null 959	
(n=3 mice/n=75 CMs examined over 3 independent experiments), Mark4+/+ MI Adv-TTL 960	
(n=3 mice / n=69 CMs examined over 3 independent experiments), Mark4-/- MI Adv-Null 961	
(n=3 mice / n=74 CMs examined over 3 independent experiments), and Mark4-/- MI Adv-TTL 962	
(n=3 mice / n= 73 CMs examined over 3 independent experiments). Colour denotation of 963	
samples (b). Resting sarcomere length (SL) (c). Average sarcomere shortening traces (d-f). 964	
Average velocity traces (dSL/dT) (g-i). j-s, Contractility assay of single CMs isolated at day 3 965	
post-MI with the following treatments: Mark4+/+ MI DMSO (n=3 mice / n=46 CMs examined 966	
over 3 independent experiments), Mark4+/+ MI PTL ( n=3 mice / n=67 CMs examined over 3 967	
independent experiments), Mark4-/- MI DMSO (n=3 mice / n=55 CMs examined over 3 968	
independent experiments), and Mark4-/- MI PTL (n=3 mice / n=64 CMs examined over 3 969	
independent experiments). Color denotation of samples (j). Resting sarcomere length (k). 970	
Sarcomere peak shortening (l). Average sarcomere shortening traces (m-o). Pooled data of 971	
contraction velocity and relaxation velocity (p). Average velocity traces (dSL/dT) (q-s). The 972	
box bounds represent the 25th and 75th percentiles, the middle line shows the median, and the 973	
whiskers show the minimum and maximum (c, k, l, p). Mean±s.e.m.; two-way ANOVA test 974	
with Bonferroni post-hoc correction for multiple comparisons (c, k, l, p). P values are 975	
indicated on the graphs. 976	
 977	
Extended Data Fig. 6.  The association of MAP4 or VASH2 with the polymerized 978	
microtubules. 979	
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a, Protein sequence alignment between human MAP4 (NP002366) and mouse MAP4 980	
(NP001192259). KXGS motifs (highlighted with red frames) within the tubulin binding 981	
repeats (highlighted with yellow, brown, dark brown, and purple frame) of MAP4 are 982	
MARK4 substrate sites. S941 of human MAP4 (S914 of mouse MAP4) and S1073 of human 983	
MAP4 (S1046 of mouse MAP4) are conserved phosphorylation sites within KXGS motifs. b, 984	
Schematic illustration of possible association between MAP4 and microtubules pre- or post- 985	
MARK4-dependent phosphorylation. Non-phosphorylated MAP4 binds to microtubules. 986	
Upon MARK4-dependent phosphorylation of mS914 at the microtubule weak binding site, 987	
MAP4 makes allosteric changes. Upon MARK4-dependent phosphorylation of mS1046 at the 988	
microtubule anchor site, MAP4 detaches from microtubules. c-d, Representative gel image of 989	
4R-MAP4 (1-4 µM) binding to the polymerized microtubules (MTs) (5 µM) in a microtubule 990	
co-sedimentation assay (c). Quantification of the binding (d). n=7 samples examined over 3 991	
independent experiments (1 µM); n=4 samples examined over 3 independent experiments (2 992	
µM); n=6 samples examined over 3 independent experiments (3 µM); n=3 samples examined 993	
over 3 independent experiments (4 µM). e-f, Representative gel image of VASH2/SVBP (0.5-994	
2 µM) binding to the polymerized MTs (2.5 µM) in a microtubule co-sedimentation assay (e). 995	
Quantification of the binding (f). n=7 samples examined over 5 independent experiments (0.5 996	
µM); n=7 samples examined over 5 independent experiments (1 µM); n=4 samples examined 997	
over 3 independent experiments (1.5 µM); n=4 samples examined over 3 independent 998	
experiments (2 µM). Mean±s.e.m.; one-way ANOVA test (d, f). P values are indicated on the 999	
graphs.  1000	
1001	
Extended Data Fig. 7. Association of VASH2 with cardiomyocyte microtubules  pre- and 1002	
post-myocardial infarction, and impact of MAP4 knock-down.  1003	
42	
a,  Subcellular fractionation on primary cardiomyocytes (CMs) isolated from mice at baseline 1004	
(BL) or post-myocardial infarction (MI). Western blotting (WB) of the fractions from 1005	
cytosolic extraction buffer (CEB) or pellet extraction buffer (PEB). b, Representative WBs of  1006	
F1 (free tubulin fraction) and F2 (extraction from the stable pellet fraction) fractions obtained 1007	
from a conventional fractionation method. c-e, WBs of CEB or PEB fractions of wild-type 1008	
(WT) CMs at baseline, or post-MI. Representative WBs (derived from the same experiment) 1009	
(c). Quantification of pMAP4S1046 in CEB, pMAP4S914 in PEB, and VASH2 levels in PEB 1010	
(n=5 mice at BL, n=6 mice post-MI, blots were processed in parallel) (d). Correlation 1011	
between VASH2 level in the PEB fraction and phosphorylated MAP4 (pMAP4) levels (e). f-i, 1012	
WT post-MI CMs transduced with adenovirus (Adv)-mediated shRNA Map4, or control 1013	
(Ctrl). Representative WBs of CEB fraction or PEB fraction, and Coomassie stained gels 1014	
loaded with the same amounts of proteins (f). Quantification of VASH2 levels in PEB (n=3 1015	
mice examined over 3 experiments per group) (g). (h-i), STED images of VASH2 and a-1016	
tubulin (a-tub) in the cardiomyocytes after knocking down MAP4. Representative images, 1017	
scale bar=2 µm (h). Pearson Correlation Coefficient (PCC) of VASH2 and a-tubulin (a-tub) 1018	
signals. percentage (%) of VASH2 signals on the polymerized microtubules (MTs), and 1019	
percentage of VASH2 signals off the polymerized MTs, in the following groups (i): shRNA 1020	
Ctrl (n=2 mice / n=35 CMs examined over 2 independent experiments), and shRNA Map4 1021	
(n=2 mice / n=27 CMs examined over 2 independent experiments ). Mean±s.e.m.; two-tailed 1022	
unpaired t-test (d, g, i); two-tailed correlation test (e). P values are indicated on the graphs. 1023	
1024	
Extended Data Fig. 8. The status of VASH2 and MAP4 in cardiomyocytes pre- and post-1025	
myocardial infarction.  1026	
a, Subcellular fractionation on wild-type (WT) cardiomyocytes (CMs), isolated from mice 1027	
post-myocardial infarction (MI) and transduced with adenovirus-mediated shRNA Vash2 or 1028	
43	
control (Ctrl). Representative western blots (WBs) of fraction in pellet extraction buffer 1029	
(PEB), with the same membrane stained with Ponceau S. b, Representative WB of PEB 1030	
extractions denatured in the presence of urea (or not), from post-MI CMs. c-d, STED images 1031	
of MAP4 and a-tubulin (a-tub) in CMs of Mark4-/- or control mice at baseline (BL) or post-1032	
MI. Oligomerized puncta are indicated within the square frames. Representative images, scale1033	
bar=2 µm (c). Quantification of the presence of the MAP4 oligomerized puncta in the 1034	
following groups (d): Mark4+/+ BL (n= 2 mice / n= 22 CMs examined over 2 independent 1035	
experiments), Mark4+/+ MI (n=2 mice / n=26 CMs examined over 2 independent 1036	
experiments), and Mark4-/- MI (n=2 mice / n=21 CMs examined over 2 independent 1037	
experiments). e-g, WB of native gels loaded with samples in cytosolic extraction buffer 1038	
(CEB) of CMs isolated at baseline (BL) or post-MI. The presence of pMAP4S1046 and total 1039	
MAP4 is indicated (e). Coomassie stained native gel loaded with the same amounts of 1040	
proteins as used in e (f). WB of CEB fraction denatured in the presence of urea, with 1041	
Coomassie stained denaturing gel loaded with the same amounts of protein (g). h-j, WB of 1042	
fractions in PEB, of CMs isolated from Mark4-/- or control mice post-MI, with Coomassie 1043	
stained gel loaded with the same amounts of proteins (h). Quantification of VASH2 and 1044	
DESMIN levels in PEB fraction (n= 4 mice per group) (i).  Correlation between DESMIN 1045	
and VASH2 levels in PEB (j). Mean±s.e.m.; two-tailed unpaired t-test (d, i); two-tailed 1046	
correlation test (j). P values are indicated on the graphs. 1047	
1048	
Extended Data Fig. 9. MARK4 overexpression regulates MAP4 phosphorylation, and 1049	
presence of MAP4 oligomers in the cytosolic fraction. 1050	
a-c, Subcellular fractionation on wild-type cardiomyocytes (CMs) transduced with adenovirus1051	
to overexpress (o.e.) Mark4 or a null control (Ctrl). Representative western blots (WBs) of 1052	
fractions in cytosolic extraction buffer (CEB) or pellet extraction buffer (PEB) (derived from 1053	
	 44	
the same experiment) (a). Quantification of pMAP4S1046 in CEB, and VASH2 level in PEB 1054	
(n=5 mice per group, blots were processed in parallel) (b). Correlation between VASH2 level 1055	
in the PEB fraction and phosphorylated MAP4 (pMAP4) levels (c). d-e, STED images of 1056	
MAP4 and a-tubulin (a-tub) in wild-type baseline CMs transduced with adenovirus to 1057	
overexpress Mark4 or a null control. Representative images, scale bar=2 µm (d). 1058	
Quantification of MAP4 oligomerized puncta in the following groups (e): o.e. Ctrl (n=2 mice 1059	
/ n=20 CMs examined over 2 independent experiments), and o.e. Mark4 (n= 2 mice / n= 24 1060	
CMs examined over 2 independent experiments). Mean ± s.e.m.; two-tailed unpaired t-test (d, 1061	
e); two-tailed correlation test (c). P values are indicated on the graphs. 1062	
  1063	
Extended Data Fig. 10. VASH2 status in cardiomyocytes pre- and post-myocardial 1064	
infarction, and the schematic summary of the results. 1065	
a-b, STED images of VASH2 and a-tubulin (a-tub) in wild-type (WT) cardiomyocytes 1066	
(CMs) at baseline (BL) or post-myocardial infarction (MI). Representative images, scale 1067	
bar=2 µm (a). Pearson Correlation Coefficient (PCC) of VASH2 and a-tub signals, 1068	
percentage (%) of VASH2 signals on the polymerized microtubules (MTs), and percentage of 1069	
VASH2 signals off the MTs, in the following groups (b): WT BL (n=4 mice / n=38 CMs 1070	
examined over 2 independent experiments), and WT MI (n=38 CMs of n=6 mice / n=38 CMs 1071	
examined over 3 independent experiments). c, Real-time PCR on post-MI CMs, from the 1072	
following groups: Mark4+/+ MI (n= 5 mice), and Mark4-/- MI (n=6 mice). d, Quantification of 1073	
VASH2 mean fluorescence intensity (MFI) within cell area (region of interest, ROI) using the 1074	
STED images from the following groups: Mark4+/+ MI (n=6 mice / n= 38 CMs examined over 1075	
3 independent experiments), and Mark4-/- MI (n= 6 mice/ n= 47 CMs examined over 3 1076	
independent experiments). Mean ± s.e.m.; two-tailed unpaired t-test (b, c, d). P values are 1077	
indicated on the graphs. e, A working model for MARK4-dependent regulation of 1078	
45	
microtubule detyrosination after MI: Upon ischaemic injury, increased MARK4 1079	
phosphorylates MAP4 at its KXGS motifs. Phosphorylated MAP4 either changes its 1080	
conformation on the polymerized microtubules, or detaches itself from the polymerized 1081	
microtubules to form oligomerized MAP4 structures in the cytosol. The phosphorylation of 1082	
MAP4 by MARK4 allows for space access of VASH2 to the polymerized microtubules, 1083	
thereby promoting a-tubulin detyrosination. As a consequence, the increased level of 1084	
detyrosinated microtubules causes a reduction in contractile function of the cardiomyocyte. 1085	
c
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